AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00742768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 in Gelpell
Description: 4 Gelpell capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 Gelpell capsules containing 30 µg MK-4 per capsule
Study NCT02069899 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Emapalumab
Description: Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.
Study NCT00637988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rofecoxib
Description: 25mg once daily
Study NCT02507167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: mixed meal
Description: 250 ml Fortimel compact (chocolate)
Study NCT02507167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: mixed meal
Description: 250 ml Fortimel compact (chocolate)
Study NCT02507167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: oral rifampin administration (600 mg EREMFAT®)
Study NCT03413501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MUD-PI
Study NCT01181011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine/telmisartan/combination
Description: patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
Study NCT02559440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate
Description: 50μg, 1 puff in each nostril every evening
Study NCT02559440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 puff in each nostril every evening
Study NCT02559440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline + Placebo
Description: 1 puff of Oxymetazoline +1 puff of Placebo in each nostril every evening
Study NCT02559440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + placebo
Description: 1 puff of placebo +1 puff of Placebo in each nostril every evening
Study NCT03543228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MyoStrain
Description: MyoStrain quantifies myocardial contraction to detect changes in heart function during chemotherapy.
Study NCT03158285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.
Study NCT02559440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate + Placebo
Description: 1 puff of mometasone furoate +1 puff of Placebo in each nostril every evening
Study NCT02559440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate + Oxymetazoline
Description: 1 puff of mometasone furoate +1 puff of Oxymetazoline in each nostril every evening
Study NCT03808727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
Study NCT03808727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
Study NCT03461328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulphate
Description: intra-operative infusion of of 10% MgSO2 , stating by a laoding dose of 30be used, a loading dose of 30 mg/kg over 20 min followed by continuous infusion of 10 mg/kg/hr accomplish the total laryngectomy.
Study NCT00372502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified EGDT
Description: Early goal directed therapy with lactate clearance
Study NCT00372502 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard EGDT
Description: Early goal directed therapy
Study NCT01548339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: 3 trocars laparoscopic cholecystectomy
Study NCT01548339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: 3 trocars laparoscopic cholecystectomy
Study NCT03158285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as SC injection.
Study NCT01918748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic Master
Description: The Haptic Master (HM) is a haptic device controlled according to the principles of 'admittance control'. In admittance control 'force' applied to the system (i.e. the HM arm) is measured, while 'position' (of the HM arm) is the end result.
Study NCT04270370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3478045
Description: Administered orally.
Study NCT04270370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT04270370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally.
Study NCT04270370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally.
Study NCT02613026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirarubicin
Study NCT02613026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02613026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT03464175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerogen Solo®
Description: Aerosol particles are generated by a vibrating-mesh nebulizer specifically designed for mechanical ventilation
Study NCT03464175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated-humidified circuit
Description: It will be left on during the transfer and the nebulization in group 1
Study NCT03464175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated-humidified circuit
Description: It will be turned off 30 minutes before the nebulization (nebulization ended max 45 minutes after turning off the heated-humidifier).
Study NCT03464175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry ventilator circuit specific for aerosol therapy
Description: Streamlined components, specific position for the nebulizer at 30 cm of a V-shaped Y piece
Study NCT03464175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dry ventilator circuit with HME filter
Description: The nebulizer is placed between the filter and the endotracheal tube.
Study NCT02744040 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ART initiation at time of HIV diagnosis
Description: Immediate ART initiation
Study NCT02744040 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ART at 24 weeks
Description: ART initiation 24 weeks after enrollment
Study NCT01740453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 2 mg/ml
Description: single
Study NCT03323567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD Muscle GUNA collagen
Description: intramusclular injections of MD Muscle collagen
Study NCT03323567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution
Description: intramuscular Lidocaine 2% injection
Study NCT03323567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution, Hypertonic
Description: intramuscular Saline injection
Study NCT04499352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: BI 754091
Study NCT04499352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: BI 836880
Study NCT00886678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, IV, q 21 days x 2 cycles
Study NCT00886678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=5,IV,q 21 days x 2 cycles
Study NCT00886678 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiation
Description: 66 Gy over 33 fractions
Study NCT01221311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully covered Metallic Stent
Description: Covered Wallflex Biliary (TM)
Study NCT01221311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic Stent
Description: Patients randomized to the PS group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and one or two PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing ERCPs, until the stricture has been obliterated using clinical and fluoroscopic criteria.
Study NCT01192009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: 7.2 g of leucine during 2 weeks
Study NCT01192009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.2 g of alanine during 2 weeks
Study NCT03913338 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: LasikXtra
Description: By randomized selection, one eye was treated with the LASIK Xtra procedure that consists of fs-LASIK treatment combined with intraoperative accelerated continuous UV-riboflavin crosslinking. After laser ablation, the corneal bed under the flap was coated with riboflavin, rinsed with saline solution, and after 90 seconds the corneal flap was repositioned. The eye was irradiated at 30 mW/cm2 for 90 seconds with continuous UVA.
Study NCT03913338 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: LASIK
Description: Femtosecond-assisted preparation of a corneal flap and subsequently excimer-laser ablation of corneal stroma. Repositioning of the corneal flap and installation of a therapeutic contact lens.
Study NCT00504972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hLL1
Description: hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
Study NCT03702413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Description: Acute thrombectomy
Study NCT02152917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Study NCT02152917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Floseal®
Study NCT01763008 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
Study NCT02035254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based Wellness Program
Description: Web-based educational modules and physical activity and/or health weight challenges
Study NCT02035254 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Web-based Wellness Program
Description: Web-based educational modules and physical activity and/or health weight challenges
Study NCT04103580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo elicitation
Description: Caregivers are taught to use photos to illustrate various feelings and meanings
Study NCT03407716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: American Ginseng
Description: Given PO
Study NCT03407716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03407716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03407716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03407716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Correlative studies
Study NCT03407716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Correlative studies
Study NCT03878641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children in Grade 1 to 5 with literacy and language needs
Description: The investigators deliver a telepractice-based intervention targeting: (a) Word reading and phonics instruction, (b) applying a comprehension monitoring strategy to improve text reading accuracy, and (c) complex sentences use in written text. Participants receive 3 online 50-minute tutoring session weekly across 15 weeks.
Study NCT02869659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Group
Description: All participants will follow the Medifast Achieve TM 4 \& 2 \& 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack
Study NCT02869659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Weight Loss
Description: 18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program
Study NCT02569099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caregiver training
Description: One hour training of family caregivers on the basic function of the brain and the stroke condition and its management in the home.
Study NCT02551042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrogammin®P, coagulation factor XIII concentrate (Human)
Description: IV infusion
Study NCT02551042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: IV infusion
Study NCT00963118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant based nutrition bar
Description: Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.
Study NCT00963118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: plant based nutrition bar
Description: Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.
Study NCT00003745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT02894268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 100g po bid
Study NCT02894268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Furazolidone 100mg po bid
Study NCT02894268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole 20mg po bid
Study NCT02894268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 20mg po bid
Study NCT02894268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Subcitrate
Description: Bismuth 20mg po bid
Study NCT02894268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal Bismuth Subcitrate
Description: Bismuth 20mg po bid
Study NCT02894268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sensitivity antibiotics
Description: Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.
Study NCT00661427 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Cetuximab 500 mg/m\^2 IV over 2 hours every other week
Study NCT00661427 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Cetuximab 750 mg/m\^2 IV over 3 hours every other week
Study NCT02093195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Study NCT02093195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort turbuhaler
Study NCT02093195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort turbuhaler
Study NCT02973438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia (IH)
Description: Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.
Study NCT02973438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM
Description: Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).
Study NCT01892839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low dialysate flow, smaller dialyzer
Description: The subject will receive dialysis on the usual schedule and for the usual time but with a lower than usual dialysate flow and small dialyzer.
Study NCT01892839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high dialysate flow, larger dialyzer
Description: The subject will receive dialysis on the usual schedule and for the usual time but with a higher than usual dialysate flow and large dialyzer.
Study NCT04291989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimal Blood Sampling Site for Point of Care Lactate Assessment using the handled Lactate-Pro 2 device
Description: This study aims to compare lactate levels using the Lactate Pro 2 device from the same patient at the same time with blood samples taken from three locations - fingertip, earlobe and forearm venepuncture
Study NCT03726229 — intervention group
Intervention type: DEVICE
Intervention: Cholate assay
Description: Labeled oral and IV cholate will be administered once to the Fontan cohort and blood specimens will be collected at baseline and timepoints thereafter.
Study NCT04137939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart exercise system
Description: The smart exercise system contains an upper extremity ergometer (UEE) and a lower extremity ergometer (LEE). The revolutions per minute (RPM) of the ergometer are instructed to maintain in 55-65. The resistance of UEE is set from level 1 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session. The resistance of LEE is set from level 2 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session.
Study NCT02110459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080
Description: Intravenous infusion
Study NCT00085735 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard volume boost (whole posterior fossa radiation therapy)
Study NCT00085735 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo standard volume boost (whole posterior fossa radiation therapy)
Study NCT00085735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00085735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT04294810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
Study NCT04294810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
Study NCT01358955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group cognitive intervention
Description: The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
Study NCT02544685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probio-Fix Inum
Description: Dose of Probio-Fix Inum: 1 capsule daily first 14 days + 1 capsule twice daily for the rest of prophylaxis duration~Probio-Fix Inum: each capsule contains 2.7 billion lyophilized probiotic bacteria Lactobacillus rhamnosus GG, LGG, American Type Culture Collection (ATCC) 53103 and Bifidobacterium animalis subspecies. lactis BB-12 Chr. Hansen Beneo Synergy 1: oligofructose-enriched inulin